# Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection

> **NCT04756271** · PHASE3 · COMPLETED · sponsor: **Zagazig University** · enrollment: 246 (actual)

## Conditions studied

- Vaccine Adverse Reaction
- Seroconversion

## Interventions

- **BIOLOGICAL:** SARS-Cov-2 neutralizing antibody titer

## Key facts

- **NCT ID:** NCT04756271
- **Lead sponsor:** Zagazig University
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-11
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-22
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04756271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04756271, "Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04756271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*